A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma

Inclusion Criteria: 1. Voluntary participation and written informed consent; 2. Aged 18-75 years (inclusive), males and females; 3. Those with histopathologically diagnosed iCCA, who had previously undergone but failed first-line systematic chemotherapy; 4. FGFR2 fusion/rearrangement confirmed by tests conducted in designated central laboratory; 5. At least one measurable lesion that has not been treated locally; 6. ECOG score of 0-1; 7. Expected survival ≥ 12 weeks; Exclusion Criteria: 1. Presence of multiple factors affecting oral medications; 2. Wounds unhealed over a long period of time, or fractures not completely healed; 3. Known or suspected allergy to investigational drug or any drug related to this trial. 4. Known cases of CNS(Central Nervous System) metastasis; 5. Uncontrolled cardiac diseases or symptoms; 6. Patients with congenital or acquired immunodeficiency (such as HIV positive), or a history of organ transplants; 7. Patients previously treated with FGFR inhibitors (such as erdafitinib)